Vernalis rated at buy by Merrill

Merrill Lynch analyst Robin Campbell gave Vernalis a buy rating on news of the company's broader pipeline that has a good chance of success in helping treat Parkinson's disease. The acquisition of Apokyn and the purchase of Cita Pharmaceuticals have strengthened Vernalis' cash position. Shares of the Cambridge, England-based pharmaceutical company were up 1p, or 1.52%, at 67p on volume of 16,828 shares versus the three-month running average of 549,493 shares. (London: VER)

Gilead reiterated at market perform by JMP

JMP Securities analyst Adam Cutler reiterated Gilead Sciences, Inc. at market perform following the Food and Drug Administration's approval of Atripla, a triple combination pill for HIV treatment that contains Gilead's Viread and Emtriva, and Bristol Myers' Sustiva. Gilead currently markets Truvada, a combination of Viread and Emtriva. Gilead will receive the same net revenue from an Atripla prescription as a Truvada prescription, according to the analyst, who is not changing the net revenues model for the company. Shares of the Foster City, Calif.-based biopharmaceutical company were down 69 cents, or 1.12%, at $61.10 on volume of 4,256,512 shares versus the three-month running average of 5,435,670 shares. (Nasdaq: GILD)

Merrill keeps Gilead at neutral

Gilead Sciences, Inc. was maintained at a neutral rating by Merrill Lynch analyst Eric Ende. The Food and Drug Administration's approval of Atripla for HIV is not expected to impact the company's earnings per share. The analyst does not expect the pill to meaningfully expand the HIV franchise, as Truvada captures 60% of new patient share. Shares of the Foster City, Calif.-based biopharmaceutical company were down 69 cents, or 1.12%, at $61.10 on volume of 4,256,512 shares versus the three-month running average of 5,435,670 shares. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.